On Aug. 18, 2025, Novo Nordisk announced the launch of a new offer that enables self-paying, eligible, type 2 diabetes patients access to authentic, FDA-approved Ozempic^® (semaglutide) for $499 per month, as part of the company’s ongoing effort to explore new collaborations and approaches to improving access to authentic semaglutide medicines. This offer is available through multiple platforms to eligible patients with a prescription for Ozempic^® and aims to assist type 2 diabetes patients who may potentially face prices at or above wholesale cost that are uninsured or choose to self-pay.

Ozempic^® is the GLP-1 with the most FDA-approved uses for patients with type 2 diabetes including, improvement of blood sugar, along with diet and exercise, in adults with type 2 diabetes, risk reduction of major cardiovascular events such as heart attack, stroke, or death in adults also with known cardiovascular (CV) disease, lowering the risk of worsening kidney disease, kidney failure (end-stage kidney disease), and death due to CV disease in adults who also have chronic kidney disease. Today, millions of people have taken Ozempic^® in the US to help address these chronic conditions, yet there are still some without adequate coverage seeking improved access.

The offer is available through multiple platforms so that patients with a prescription for real, FDA-approved Ozempic^® can access it in the way that suits them best. For the first time, Ozempic^® is available through NovoCare^® Pharmacy.

In addition, Novo Nordisk is collaborating with GoodRx, the leading platform for medication savings in the U.S., to offer both Wegovy^® (for adults with obesity) and Ozempic^® (for adults with type 2 diabetes) at $499 per month through the GoodRx platform, making this price available to eligible self-paying patients at more than 70,000 pharmacies nationwide. The relationship with GoodRx is another example of Novo Nordisk teaming up with healthcare companies who have a shared commitment to driving access and affordability for patients seeking Novo Nordisk’s authentic, FDA-approved medicines for their approved uses.

Novo Nordisk is continuing to take multiple proactive measures to keep patients aware of potentially unsafe and unapproved knockoff alternatives and informed of how to access authentic, FDA-approved medicines. More information can be found on semaglutide.com.